APLS.D

Apellis Pharmaceuticals, Inc.

Biotechnology · Biotechnology

$226.65 sample

+3.30 (+1.48%) 1D

Market cap

$157.0B

Price as of

2026-10-24

Latest filing

8-K · 2026-10-20

Alerts

8

Price$226.65 +12.38% 3M daily closessample

226.65200.67

2026-07-282026-08-192026-09-102026-10-012026-10-23

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 20SECDEF 14A filed
Oct 09INSInsider sell: Chief Executive Officer
Oct 05SEC10-Q filed
Sep 24INSInsider buy: Chief Financial Officer
Sep 21INSInsider sell: General Counsel
Sep 16SEC10-Q filed
Sep 11SECForm 144 filed
Sep 02INSInsider buy: Chief Financial Officer

Sign up to see the real APLS.D record →

Company facts

SEC EDGAR registration

Name: Apellis Pharmaceuticals, Inc.
Sector: Biotechnology
Industry: Biotechnology
Smart-money score: +5sample, -100 to +100
Reporting currency: USD

Who is positioning in APLS.D

sample

Insiders: 30 insider transactions over 90 days, net selling, $614.0M
Congress: 2 members traded over 90 days
Institutions · 13F: 7 funds hold $2.2B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$3.9B +18.7% y/y

Q4 2024Q3 2026

Inventory$2.2B +12.9% y/y

Q4 2024Q3 2026

Accounts receivable$1.7B +16.8% y/y

Q4 2024Q3 2026

Total debt$4.6B +11.6% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $110.2B +11.5% 3M
Sample peer B: $139.6B -3.9% 3M
Sample peer C: $85.7B +6.8% 3M
Sample peer D: $84.2B +1.9% 3M
Sample peer E: $40.1B -9.5% 3M